Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000004

Drug Information
NameDasatinib    
Synonyms302962-49-8; LS-186641; MolPort-003-846-143; EC-000.2122; LS-187773; BCB03_000715; CHEBI:49375; 1N1; UNII-X78UG0A0RN; BMS-354825, Sprycel, BMS354825, Dasatinib; 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide; SPRYCEL (TN); nchembio.117-comp11; Sprycel; Dasatinib anhydrous; S1021_Selleck; NSC-732517; CHEMBL1421; LS-187028; N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; FT-0084503; Dasatinib (USAN); CID3062316; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; Kinome_3650; I14-1972; BMS354825; dasatinibum; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-; AC1MI3ET; BMS 354825; N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; AC1Q2P0C; D03658; Dasatinib, BMS 354825; EN002710; C488369; nchembio.162-comp4; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-; (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; DB01254; N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate; Spyrcel; NCGC00181129-01; Dasatinib; BMS-354825; AmbotzLS-1203; nchembio.332-comp1; NSC732517; Dasatinib [USAN]    
Trade NameSprycel    
CompanyBristol Myers Squibb    
IndicationChronic myelogenous leukemia Launched    [1]
Solid tumours, multiple myelomaPhase II    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAntineoplastic Agents    
CAS NumberCAS 302962-49-8
FormularC22H26ClN7O2S    
PubChem Compound IDCID 3062316.    
PubChem Substance IDSID 3865636.    
ChEBI49375;    
TargetProto-oncogene tyrosine-protein kinase SRCInhibitor[2][3][4]
Proto-oncogene tyrosine-protein kinase FynMultitarget[2][3][4]
Proto-oncogene tyrosine-protein kinase LCKInhibitor[2][3][4]
Proto-oncogene tyrosine-protein kinase FynInhibitor[2][3][4]
Proto-oncogene tyrosine-protein kinase SRCMultitarget[2][3][4]
Proto-oncogene tyrosine-protein kinase ABL1Inhibitor[2][3][4]
Proto-oncogene tyrosine-protein kinase ABL1Multitarget[2][3][4]
Proto-oncogene tyrosine-protein kinase LCKMultitarget[2][3][4]
Ref 1Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27. To Reference
Ref 2A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference
Ref 3In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc. J Clin Pharmacol. 2008 Oct;48(10):1179-88. Epub 2008 Aug 1. To Reference
Ref 4Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. Epub 2006 Nov 28. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543